<DOC>
	<DOCNO>NCT00474786</DOCNO>
	<brief_summary>This international , randomize , open-label , outpatient , multicenter study . Subjects assign 1:1 ratio 1 2 treatment arm : temsirolimus 25 mg weekly intravenous ( IV ) infusion sorafenib 400 mg mouth ( PO ) twice daily ( BID ) . These investigational drug administer 6-week cycle duration study , 24 month . Subjects stratify nephrectomy status , duration response sunitinib therapy , Memorial Sloan Kettering Cancer Center ( MSKCC ) prognostic group , RCC tumor histology .</brief_summary>
	<brief_title>Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically confirm diagnosis mRCC ( regardless histology nephrectomy status ) welldocumented Radiological PD RECIST criterion clinical PD judge investigator receive firstline sunitinib therapy . Subjects must least 1 cycle sunitinib therapy ( minimum four week continuously ) . At time randomization , least 2 week since prior treatment sunitinib , palliative radiation therapy , and/or surgery . At time randomization , must least 1 measurable lesion per RECIST . Lesions previously irradiate embolized select target lesion . More criterion apply Metastatic CNS RCC . Subjects discontinue Sutent therapy due specifically intolerance . Prior systemic therapy mRCC sunitinib . Active ketonuria , secondary poorly control diabetes mellitus More criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Metastatic Advanced Renal Cell Carcinoma</keyword>
</DOC>